文献速递中医内科中药与中成药合理使用

中药治疗溃疡性结肠炎:产品级临床证据、机制评价与精准转化路线图

Chinese herbal medicine for ulcerative colitis: product-level clinical evidence, mechanistic appraisal, and a roadmap to precision translation.
PubMed 文献 · Front Pharmacol · 2026-10-08

本文是一篇批判性叙述综述,指出中药治疗溃疡性结肠炎因产品异质性、试验质量不一和长期安全性数据有限,无法做类别级疗效声明。综述以定义明确的植物药产品、制剂、给药途径、剂量和工艺为评价单元,聚焦传统方剂、加工药材和专有制剂。多数机制声称仍属临床前且依赖模型,精准转化应视为前瞻性研究计划而非已实现的临床状态。

要点

  • 中药治疗UC的疗效证据需按具体产品评价,不能做类别级推断。
  • 高剂量姜黄素及姜黄素-青黛组合显示获益信号,低剂量姜黄素为阴性。
  • 青黛显示剂量相关疗效但伴重要安全性担忧,需加强药物警戒。

核心结论

  • 中药治疗UC无法做类别级疗效声明,应在定义产品水平评价证据。
  • 精准转化应视为前瞻性研究计划,而非已实现的临床状态。

研究设计与样本

  • 批判性叙述综述,评价单元为定义明确的植物药产品、制剂、途径、剂量和工艺。
  • 聚焦传统方剂、加工植物药和专有制剂,纯化植物代谢物仅在产品相关时讨论。

主要发现

  • 高剂量姜黄素试验和姜黄素-青黛组合提供获益信号,低剂量姜黄素为阴性。
  • 青黛显示剂量相关疗效,但伴随重要安全性担忧。
  • 最强机制证据来自人体靶点结合或因果扰动,如姜黄素-青黛诱导黏膜CYP1A1、Ahr缺陷小鼠中青黛疗效丧失。
  • 多数其他机制声称仍属临床前且依赖模型。

关键数值与推荐

  • 转化需分类学鉴定和化学表征的产品、暴露测量、因果机制测试、CORE-IBD/STRIDE-II对齐的客观结局、CONSORT-CHM报告和前瞻性批次可追溯药物警戒。
  • 尚无分子、微生物或传统证型生物标志物在定义中药产品中显示前瞻性验证的治疗-生物标志物交互作用。

临床怎么用

  • 临床选用中药治疗UC时应明确具体产品、制剂、剂量和工艺,避免类别级推断。
  • 对青黛等有安全性担忧的产品需加强监测和药物警戒。
  • 优先参考有产品级随机试验证据的中药,如高剂量姜黄素和姜黄素-青黛组合。

局限性

  • 产品异质性、试验质量不一和长期安全性数据有限限制证据强度。
  • 多数机制证据来自临床前模型,尚未在人体前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chinese herbal medicine (CHM) is widely used for ulcerative colitis (UC), but product heterogeneity, variable trial quality, and limited long-term safety data preclude class-level efficacy claims. This critical narrative review therefore evaluates evidence at the level of the defined botanical drug product, formulation, route, dose, and manufacturing process. The review focuses on traditional formulas, processed botanical drugs, and proprietary preparations with documented use in Chinese medical practice. Purified plant metabolites such as curcumin and common flavonoids are not treated as uniquely Chinese interventions; they are discussed only when they are part of a defined CHM-related product or when pivotal natural-product trials provide a relevant product-level comparator. Primary randomized trials show heterogeneous results: higher-dose curcumin trials and the curcumin-QingDai combination provide signals of benefit, low-dose curcumin was negative, and indigo naturalis shows dose-related efficacy accompanied by important safety concerns. Mechanistically, the strongest evidence comes from human target engagement or causal perturbation, exemplified by mucosal CYP1A1 induction with curcumin-QingDai and loss of indigo naturalis efficacy in Ahr-deficient mice. Most other mechanistic claims remain preclinical and model-dependent. Translation requires taxonomically authenticated and chemically characterized products, measured exposure, causal mechanism testing, objective CORE-IBD/STRIDE-II-aligned outcomes, CONSORT-CHM reporting, and prospective, batch-traceable pharmacovigilance. No molecular, microbial, or traditional-pattern biomarker has yet shown a prospectively validated treatment-by-biomarker interaction for a defined CHM product. Precision translation should therefore be regarded as a prospective research program rather than an achieved clinical state.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wu Y, Ren J, Li H, et al. Chinese herbal medicine for ulcerative colitis: product-level clinical evidence, mechanistic appraisal, and a roadmap to precision translation. Front Pharmacol. 2026. PMID: 42923132. doi:10.3389/fphar.2026.1976448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。